Holen Sie sich die Stockscreener-App
3.56
2.76%
-0.06
Schlusskurs vom Vortag:
$3.62
Offen:
$3.6
24-Stunden-Volumen:
5,625
Relative Volume:
0.01
Marktkapitalisierung:
$4.78M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-11.00M
KGV:
-8.999
EPS:
-0.3956
Netto-Cashflow:
$-11.99M
1W Leistung:
-8.33%
1M Leistung:
-31.65%
6M Leistung:
-69.85%
1J Leistung:
-97.13%
1-Tages-Spanne:
$3.5182
$3.6185
1-Wochen-Bereich:
$3.5182
$3.91
52-Wochen-Spanne:
$3.42
$141.50
Liminatus Pharma Inc Stock (LIMN) Company Profile
Firmenname
Liminatus Pharma Inc
Sektor
Branche
Telefon
213-273-5453
Adresse
12611 HIDDENCREEK WAY, CERRITOS
Compare LIMN vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LIMN
Liminatus Pharma Inc
|
3.56 | 4.86M | 0 | -11.00M | -11.99M | -0.3956 |
VRTX
Vertex Pharmaceuticals Inc
|
522.11 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.76 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,004.25 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.30 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.67 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Liminatus Pharma Inc Aktie (LIMN) Neueste Nachrichten
Enterprise value to EBITDA forward of Liminatus Pharma, Inc. – NASDAQ:LIMNW - TradingView
Price to sales forward of Liminatus Pharma, Inc. – BOATS:LIMNW - TradingView
Liminatus Pharma selects Synex to advance CAR-T trial - Clinical Trials Arena
Liminatus engages Synex for IBC101 CAR-T clinical development - Investing.com
Liminatus Pharma Engages Synex Consulting to Support Clinical Development of IBC101 CAR-T Therapy in South Korea - Quiver Quantitative
Liminatus engages Synex for IBC101 CAR-T clinical development By Investing.com - Investing.com UK
Korea’s Ministry of Food and Drug Safety authorizes Liminatus study - Stock Titan
Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy - Yahoo Finance
Nasdaq Orders Immediate Suspension of Flash Sports & Media Stock - Minichart
Press Releases about Liminatus Pharma, Inc.Class A Common Stock (Nasdaq:LIMN) - FinancialContent
17,272,739 Common Stock of Liminatus Pharma, Inc. are subject to a Lock-Up Agreement Ending on 19-AUG-2026. - marketscreener.com
Liminatus Pharma to implement 1-for-50 reverse stock split - Investing.com
Liminatus Pharma Enacts Reverse Split to Maintain Listing - TipRanks
Liminatus Pharma announces 1-for-50 reverse stock split - TipRanks
Liminatus Pharma to implement 1-for-50 reverse stock split By Investing.com - Investing.com India
Liminatus Pharma Announced Transfer or Voluntary Withdrawal of Listing - TradingView
Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock - The Manila Times
Liminatus Pharma, Inc. Announces Reverse Stock Split of Its Common Stock - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Liminatus Pharma (LIMN) Stock Analysis Report | Financials & Insights - Benzinga France
Liminatus Pharma Warrants (LIMNW) Tumble 13.79% to $0.05 as Key Level Comes Into FocusScalping Stock Signals - vinanet.vn
Liminatus Pharma (LIMN) Slides 6.6% to $0.14, Testing Critical $0.13 SupportLow Vol ETF - vinanet.vn
Liminatus Pharma, Inc. Q2 2026: Net income $(1.41)M, EPS $(0.03) — 10-Q Summary - TradingView
Liminatus Pharma (LIMN) logs $2.5M loss and fights Nasdaq listing threats - Stock Titan
Liminatus Pharma (LIMN) Stock Jumps Over 50% on a Listing Update - TipRanks
These stocks are the most active in today's session - ChartMill
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Liminatus Pharma moves to Nasdaq Capital Market By Investing.com - Investing.com Nigeria
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Liminatus Pharma moves to Nasdaq Capital Market - Investing.com
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement - The Manila Times
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Bid Price Compliance - Quiver Quantitative
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance ... - Herald and News
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance With Minimum Bid Price Requirement - Moomoo
$Liminatus Pharma (LIMN.US)$ - moomoo.com
Liminatus Pharma Warrants (LIMNW) Jump 34% to $0.07 as Traders Eye Key Inflection PointFear Greed Extreme - vinanet.vn
Liminatus Pharma (LIMN) Edges Higher as Micro-Cap Biotech Holds Key $0.10 Support LevelTriple Bottom - dars.gov.et
Liminatus Pharma Shareholders Approve Reverse Stock Split Plan - The Globe and Mail
Liminatus Pharma Warrants (LIMNW) Remain Flat at $0.06 as Key Levels ConvergePut Dominated - dars.gov.et
Liminatus Pharma, Inc. Primary Exchange Listing has Changed to Nasdaq Capital Market from Nasdaq Global Market - marketscreener.com
Liminatus Pharma, Inc. Revenue Breakdown – NASDAQ:LIMN - TradingView
Liminatus Pharma Reports Improved Nasdaq Listing Compliance Status - TipRanks
Liminatus Pharma (NASDAQ: LIMN) cites $2.5M equity in Nasdaq compliance review - Stock Titan
LIMN|Liminatus Pharma Ord Shs Class A|Price:4.410|Chg%:-0.200 - TradingKey
LIMN|Liminatus Pharma Ord Shs Class A|Price:0.119|Chg%:+0.002 - TradingKey
Liminatus Pharma, Inc. Revenue Breakdown – NASDAQ:LIMNW - TradingView
Liminatus Pharma Faces Nasdaq Delisting Risk, Plans Reverse Split - The Globe and Mail
Liminatus Pharma, Inc. Revenue Breakdown – BOATS:LIMN - TradingView
Liminatus Pharma Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Liminatus Pharma, Inc. Class A Common Stock (NASDAQ: LIMN) Stock Price, News & Analysis - Kalkine
Samda Biolab discloses 5.1% Liminatus Pharma (LIMN) ownership position - Stock Titan
Finanzdaten der Liminatus Pharma Inc-Aktie (LIMN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):